Latest news with #Genusplc
Yahoo
26-05-2025
- Business
- Yahoo
Institutional investors in Genus plc (LON:GNS) lost 3.3% last week but have reaped the benefits of longer-term growth
Given the large stake in the stock by institutions, Genus' stock price might be vulnerable to their trading decisions A total of 10 investors have a majority stake in the company with 51% ownership Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of Genus plc (LON:GNS) can tell us which group is most powerful. With 81% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 3.3% in value last week. However, the 12% one-year returns may have helped alleviate their overall losses. We would assume however, that they would be on the lookout for weakness in the future. Let's take a closer look to see what the different types of shareholders can tell us about Genus. See our latest analysis for Genus Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Genus does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Genus' historic earnings and revenue below, but keep in mind there's always more to the story. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It looks like hedge funds own 6.7% of Genus shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Wellington Management Group LLP is currently the largest shareholder, with 9.8% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.1% and 6.7%, of the shares outstanding, respectively. We did some more digging and found that 10 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Genus plc in their own names. Keep in mind that it's a big company, and the insiders own UK£3.6m worth of shares. The absolute value might be more important than the proportional share. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling. The general public, who are usually individual investors, hold a 11% stake in Genus. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. It's always worth thinking about the different groups who own shares in a company. But to understand Genus better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Genus . If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
28-04-2025
- Business
- Yahoo
High Growth Tech Stocks in the UK to Watch April 2025
As the UK market grapples with global economic challenges, including the ripple effects of China's sluggish recovery impacting the FTSE 100 and FTSE 250 indices, investors are keenly observing how these factors influence high-growth sectors. In such a climate, identifying tech stocks with robust growth potential involves looking for companies that demonstrate resilience and adaptability amid fluctuating market conditions. Name Revenue Growth Earnings Growth Growth Rating Facilities by ADF 26.24% 161.47% ★★★★★☆ YouGov 4.12% 64.42% ★★★★★☆ Audioboom Group 8.84% 59.33% ★★★★★☆ Pinewood Technologies Group 24.48% 41.53% ★★★★★☆ Redcentric 5.32% 67.90% ★★★★★☆ Oxford Biomedica 16.52% 82.05% ★★★★★☆ Windar Photonics 37.17% 46.73% ★★★★★☆ Trustpilot Group 15.02% 40.20% ★★★★★☆ Cordel Group 33.50% 148.58% ★★★★★☆ Vinanz 113.60% 125.86% ★★★★★☆ Click here to see the full list of 37 stocks from our UK High Growth Tech and AI Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Midwich Group plc, along with its subsidiaries, is a distributor of audio visual solutions to trade customers across various regions including the United Kingdom, Ireland, Europe, the Middle East, Africa, the Asia Pacific, and North America with a market capitalization of £189.09 million. Operations: The company generates revenue primarily from distributing computer peripherals, with a significant contribution of £1.32 billion. Amid a challenging year, Midwich Group demonstrated resilience with a revenue increase to £1,317 million from £1,295 million previously. Despite a dip in net income to £16.03 million from last year's £26.82 million, the firm is poised for significant growth with expected annual earnings growth of 22.2%. This outpaces the broader UK market forecast of 13.7% and suggests robust future prospects despite current hurdles like reduced dividends and lower profit margins (1.2% down from 2.1%). With an emphasis on expanding its technological offerings and adapting to market demands, Midwich appears well-positioned for recovery and growth in the evolving tech landscape. Dive into the specifics of Midwich Group here with our thorough health report. Explore historical data to track Midwich Group's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Genus plc is an animal genetics company with operations spanning North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia and has a market cap of approximately £1.05 billion. Operations: Genus plc generates revenue primarily through its two main segments: Genus ABS, contributing £311.10 million, and Genus PIC, contributing £358 million. The company focuses on animal genetics across various global regions. With a strategic leadership transition on the horizon, Genus plc is setting the stage for robust governance and financial oversight. Andy Russell's appointment as CFO, effective August 2025, follows his impactful tenure at Smith & Nephew, promising to infuse Genus with deep financial acumen and M&A expertise. Despite recent challenges reflected in a slight dip in sales to £336.4 million and net income falling to £1.5 million from £10.3 million last year, the company's R&D commitment remains strong, positioning it well for future innovations in biotechnology—a sector where staying ahead technologically is crucial for growth. This focus on R&D is essential as it nurtures potential breakthroughs that could significantly enhance Genus's market position and profitability in the coming years. Navigate through the intricacies of Genus with our comprehensive health report here. Learn about Genus' historical performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Trustpilot Group plc operates an online review platform serving businesses and consumers across the United Kingdom, North America, Europe, and other international markets, with a market capitalization of £913.14 million. Operations: The company generates revenue primarily from its platform as an Internet Information Provider, totaling $210.75 million. Trustpilot Group's recent innovations and strategic buybacks underscore its agile adaptation in the tech landscape. The company introduced new features enhancing customer engagement through actionable insights from reviews, a critical move as evidenced by a PWC survey highlighting trust's impact on financial performance. Furthermore, Trustpilot repurchased shares worth £13.52 million, signaling confidence in its operational strategy and financial health. Despite a slight dip in net income to $6.23 million from $7.11 million last year, the firm is poised for growth with revenue up to $210.75 million, marking a 15% increase year-over-year and outpacing the UK market's average growth rate of 3.9%. This trajectory is supported by an anticipated earnings growth of 40.2% annually, positioning Trustpilot favorably within the competitive tech sector. Click here and access our complete health analysis report to understand the dynamics of Trustpilot Group. Understand Trustpilot Group's track record by examining our Past report. Click through to start exploring the rest of the 34 UK High Growth Tech and AI Stocks now. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:MIDW LSE:GNS and LSE:TRST. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
07-03-2025
- Business
- Yahoo
UK Stocks That Might Be Trading Below Their Estimated Value In March 2025
The United Kingdom's stock market has recently experienced a downturn, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. In such an environment, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors looking to capitalize on undervaluation amid broader market challenges. Name Current Price Fair Value (Est) Discount (Est) Dr. Martens (LSE:DOCS) £0.6105 £1.19 48.6% GlobalData (AIM:DATA) £1.79 £3.37 46.9% Deliveroo (LSE:ROO) £1.257 £2.50 49.6% AstraZeneca (LSE:AZN) £120.28 £219.10 45.1% Duke Capital (AIM:DUKE) £0.3025 £0.55 44.6% Likewise Group (AIM:LIKE) £0.195 £0.37 47.6% Calnex Solutions (AIM:CLX) £0.52 £1.03 49.7% Kromek Group (AIM:KMK) £0.0585 £0.11 48.5% Optima Health (AIM:OPT) £1.82 £3.31 45% Savannah Energy (AIM:SAVE) £0.105 £0.20 48.7% Click here to see the full list of 57 stocks from our Undervalued UK Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £5.47 billion. Operations: The company's revenue is primarily generated from the development, manufacture, and sale of medical products and technologies, amounting to $2.29 billion. Estimated Discount To Fair Value: 36% ConvaTec Group appears undervalued, trading at £2.67, 36% below its estimated fair value of £4.18. The company's earnings grew by 46.2% last year and are forecast to grow annually at 16.9%, outpacing the UK market's 14.1%. Despite high debt levels, ConvaTec maintains a strong financial position with operating profit growth projected at 12% for 2025 and a net income increase to US$190.5 million from US$130.3 million in the prior year. Our growth report here indicates ConvaTec Group may be poised for an improving outlook. Take a closer look at ConvaTec Group's balance sheet health here in our report. Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa and Asia; it has a market cap of £1.25 billion. Operations: The company's revenue is derived from two main segments: Genus ABS, which contributes £311.10 million, and Genus PIC, which accounts for £358 million. Estimated Discount To Fair Value: 19% Genus plc, trading at £19.04, is undervalued relative to its fair value estimate of £23.5. Despite recent earnings showing a decline in net income to £1.5 million from £10.3 million year-on-year, analysts forecast robust profit growth of 46.67% annually over the next three years, outpacing market averages and expected to achieve profitability within this period. However, the stock exhibits high volatility and a low forecasted return on equity of 12.5%. In light of our recent growth report, it seems possible that Genus' financial performance will exceed current levels. Delve into the full analysis health report here for a deeper understanding of Genus. Overview: PageGroup plc, along with its subsidiaries, offers recruitment consultancy and related services across the UK, Europe, the Middle East, Africa, Asia Pacific, and the Americas with a market cap of £1.05 billion. Operations: PageGroup generates revenue through its recruitment consultancy and ancillary services across regions including the UK, Europe, the Middle East, Africa, Asia Pacific, and the Americas. Estimated Discount To Fair Value: 14.3% PageGroup, trading at £3.34, is undervalued compared to its fair value estimate of £3.9. Despite a decline in revenue and net income for 2024, earnings are forecast to grow significantly at 37.6% annually over the next three years, surpassing UK market averages. The company proposed a dividend increase but maintains an unstable dividend track record. Profit margins have decreased from 3.8% to 1.6%, yet return on equity is projected to be high at 35.1%. Our comprehensive growth report raises the possibility that PageGroup is poised for substantial financial growth. Unlock comprehensive insights into our analysis of PageGroup stock in this financial health report. Access the full spectrum of 57 Undervalued UK Stocks Based On Cash Flows by clicking on this link. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:CTEC LSE:GNS and LSE:PAGE. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
